Erythropoietin stimulating agents do not significantly improve quality of life in chronic kidney disease, study finds

Treating chronic kidney disease more intensively with erythropoietin stimulating agents (ESAs) to achieve higher haemoglobin levels did not improve patients’ quality of life, a meta-analysis published in the Annals of Internal Medicine has shown.1